Figure 3.
Single-chain antibody A1 differentially inhibits von Willebrand factor-platelet interaction at constant shear or gradients of shear. (A) Abciximab-treated (20 μg mL-1), citrated whole blood, labeled with 0.5 μg ml-1 DiOC6 containing single-chain antibody (scFv) A1 (5 μg mL-1) or control was perfused over a collagen III-coated surface as described in Figure 1B. Platelet adhesion was assessed at the stenosis inlet, apex, outlet and upstream areas using particle tracking software. Data represented as matched individual data points and mean ± standard error of the mean (SEM); n=5; *P<0.05. (C) Relative von Willebrand factor (VWF) amount corrected for the level per platelet in platelet aggregates under shear rate gradient (SRG) and constant shear. Data represented as mean ± SEM; n=3-4; (multiple t-test).